EVRY, France--(BUSINESS WIRE)--IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, announced today its revenues for the first half of 2013.
18% growth in Genomic Services revenue
IntegraGen SA revenues reached 2,7 M€ as of June 30, 2013, a growth of 18% compared to 2012. This increase reflects the strong demand for sequencing services and highlights the high quality of performance of IntegraGen’s laboratory which provides end-to-end genomic services from DNA or RNA extraction to bioinformatics data management.
ARISk® Test sales take off in the U.S.
The ARISk® Test, the first genetic test able to identify the risk of autism, was launched in 2012. Over the first 6 months of 2013, IntegraGen experienced a significant increase in demand from physicians interested in prescribing the test. Sales of the initial version of the test, which targets siblings of affected children, led to realized revenue of $30K USD during the first half of 2013. IntegraGen is finalizing the development of a newer version of the test which will target children with a suspicion of autism who do not have a family history of the disorder. The Company anticipates commercial availability of this new test before the end of 2013.
Promising results in Oncology
IntegraGen continues its efforts to develop a diagnostic test for metastatic colorectal cancer with a planned commercial launch in 2014. Furthermore, the Company has recently announced the publication of results regarding a prognostic molecular signature in hepatocellular carcinoma (liver cancer) in partnership with the French League against Cancer and INSERM. These results are particularly encouraging since they could represent a major breakthrough in the management of patients with liver cancer.
Bernard Courtieu, Chief Executive Officer of IntegraGen, declared “The continued growth of our genomic activities as well as the first revenues from our molecular diagnostic tests reinforce our strategic positioning and allow us to confirm our guidance for further growth and development for 2013.”
IntegraGen will publish its H1 results in October 2013.
Founded in 2000, IntegraGen (ALINT.PA) is a biotechnology company focused on the development and commercialization of molecular diagnostic tests in the fields of autism and oncology. IntegraGen’s mission is to translate molecular research into clinical practice through the identification of novel genetic biomarkers and the subsequent development of molecular diagnostic tests which allow clinicians to better manage the clinical care of their patients. IntegraGen is also a leader in delivering expert genomic service solutions to academic researchers and life sciences companies as a result of its scientific knowledge and technological expertise related to cutting edge genomic platforms and bioinformatics.
- For more information about IntegraGen visit www.integragen.com